Adaptive Biotechnologies (ADPT) is back in focus after announcing that its clonoSEQ minimal residual disease test will feature in 33 presentations at the ASCO and EHA conferences, highlighting broad use across multiple blood cancers.

At a share price of US$17.60, Adaptive Biotechnologies has seen a 34.04% 1 month share price return and a 70.54% 1 year total shareholder return, while the 5 year total shareholder return remains down 55.39%. This suggests recent momentum has picked up after a tougher longer term run.

If clonoSEQ’s presence at major oncology meetings has your attention, it could be a good moment to scan the broader opportunity set in healthcare focused AI, starting with 40 healthcare AI stocks

With clonoSEQ in the spotlight and the stock up sharply over the past year, the key question now is whether Adaptive Biotechnologies is still trading below its estimated intrinsic value or if the market is already pricing in future growth.

Most Popular Narrative: 12.6% Undervalued

With Adaptive Biotechnologies last closing at $17.60 against a narrative fair value of $20.14, the current setup centers on clonoSEQ driven growth and long term margin ambitions.

Marked improvement in profitability, with the MRD segment now EBITDA positive and company wide cash burn improving 36% year over year, signals the business reaching scale and positions Adaptive for operating leverage and expanding net margins as revenue continues to rise.

Want to see the engine behind that higher fair value? The narrative leans on faster revenue compounding, rising margins and a punchy future earnings multiple. Curious which assumptions really carry the model?

Result: Fair Value of $20.14 (UNDERVALUED)

However, there are still execution risks, including ongoing losses at the group level and reliance on key partnerships, which could challenge the current upside narrative.

Another View: Pricing Power Cuts The Other Way

The analyst driven fair value of $20.14 suggests upside, but the current P/S ratio of 9.5x paints a tougher picture. That compares with 3.7x for the US Life Sciences industry, 7.6x for peers, and a fair ratio of 4.2x that the market could move towards, which raises valuation risk if sentiment cools.

For a closer look at what the numbers imply for the current share price, including how rich that P/S ratio is versus peers and the fair ratio, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If the mixed sentiment in this article has you unsure, take a moment to consider both sides. You can review the data while it is still fresh by checking the 3 key rewards and 1 important warning sign.

Looking for more investment ideas?

Do not stop your research at a single stock. The right mix of opportunities can sharpen your edge and keep you ready when conditions shift.

• Target stability with companies that prioritize resilience and prudent finances by scanning the 70 resilient stocks with low risk scores.
• Hunt for potential mispriced opportunities by reviewing the 44 high quality undervalued stocks that combine quality with attractive valuations.
• Spot resilient cash generators by checking the solid balance sheet and fundamentals stocks screener (48 results) that pair robust balance sheets with fundamental strength.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.